drugset / Trial / NCT03493282
Effect of CT1812 Treatment on Brain Synaptic Density
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Study to Evaluate the Safety and Tolerability of Oral CT1812 in Subjects with Mild to Moderate Alzheimer's Disease.
Timeline
- Start
- 2018-03-28
- Primary completion
- 2020-10-16
- Completion
- 2020-10-16
Publications
- Lizama BN, Williams C, North HA, Pandey K, Duong D, Di Caro V, Mecca AP, Blennow K, Zetterberg H, Levey AI, Grundman M, van Dyck CH, Caggiano AO, Seyfried NT, Hamby ME. CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease. Alzheimers Dement. 2024 Oct;20(10):6860-6880. doi: 10.1002/alz.14152. Epub 2024 Aug 21.
- van Dyck CH, Mecca AP, O'Dell RS, Bartlett HH, Diepenbrock NG, Huang Y, Hamby ME, Grundman M, Catalano SM, Caggiano AO, Carson RE. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease. Alzheimers Res Ther. 2024 Jan 25;16(1):20. doi: 10.1186/s13195-024-01382-2.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CT1812 | Small molecule | 100 mg | Oral |
| Comparator | CT1812 | Small molecule | 300 mg | Oral |